Temporal trends in utilization of transcatheter aortic valve replacement and patient characteristics: A nationwide study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 932 KB, PDF-dokument

Aim: To investigate trends in the utilization of transcatheter aortic valve replacement (TAVR) and changes in the characteristics of patients undergoing first-time TAVR. Methods: Using Danish nationwide registers, we included all patients undergoing TAVR between 2008 and 2020. To compare patient characteristics, the study population was stratified according to calendar year of procedure: 2008-2010, 2011-2013, 2014-2016, and 2017-2020. Results: We identified 6,097 patients undergoing TAVR with year-by-year increases in TAVR penetration rate. Over time, the age of the patients remained stable (2008-2010: median age 82 year [interquartile range (IQR): 77-86] vs 2017-2020: median age 81 years [IQR: 77-85]). Moreover, there was an increase in male patients (2008-2010: 49.9% vs 2017-2020: 57.4%) and patients with diabetes (2008-2010: 14.2% vs 2017-2020: 19.2%). Conversely, a history of stroke (2008-2010: 15.8% vs 2017-2020: 13.1%), previous myocardial infarction (2008-2010: 22.4% vs 2017-2020: 10.0%), heart failure (2008-2010: 40.5% vs 2017-2020: 25.2%), and peripheral artery disease (2008-2010: 14.8% vs 2017-2020: 10.4) decreased among patients. Conclusions: TAVR utilization increased markedly in the years 2008-2020. Patients undergoing TAVR had less comorbidity over time while age remained stable. Thus, despite expanding to patients at lower surgical risk, TAVR is still offered mainly to older patients.

OriginalsprogEngelsk
TidsskriftAmerican Heart Journal
Vol/bind243
Sider (fra-til)140-146
Antal sider7
ISSN0002-8703
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
CTP: Grants from Bayer and Novo Nordisk not related to current study. ELF: Independent research grant from Novo Nordisk Foundation. LK: Speakers honorarium from Novartis, Novo, Boehringer and AstraZeneca. LS: Consultant fees and/or institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, SMT and Symetis. JBO: Speaker honoraria or consultancy fees from Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Novartis Healthcare, and Novo Nordisk. The other authors declare that they have no conflicts of interest relevant to the content of this manuscript.

Publisher Copyright:
© 2021

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 290110493